Temporary Peptide Sales Plan: What the October 2026 Report Means for Patients

Rx Peps Direct tracks these developments because every peptide we offer is prescribed by a licensed provider after a $39 visit and filled by a licensed U.S. compounding pharmacy. The rules that pharmacies follow decide what a provider can prescribe.

What did the Washington Post report?

The Post reported that the administration is preparing a temporary measure, not a final rule. The story, by reporter Rachel Roubein, is based on two people familiar with the plan who were not named.

• The measure would let some compounding pharmacies fill prescriptions for certain peptides during the period when new regulations are being written.
• No federal agency has announced the plan. The Alliance for Pharmacy Compounding, the trade group for compounding pharmacies, noted the same and said the details could still change.
• No start date has been published.

Which peptides are involved?

It is not known which peptides would be included. No official list has been published.

The closest official reference is the FDA advisory committee meeting of July 23 and 24, 2026, which reviewed seven peptides: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax and Epitalon. The committee recommended six for the list of substances compounding pharmacies may use and voted against emideltide. Rx Peps Direct prescribes all seven, including the one the committee voted against. Until an official document names the peptides in this plan, treat any list you read as unconfirmed.

Has the FDA approved BPC-157 or any of these peptides?

No. None of these peptides is FDA approved, and a temporary sales measure would not change that.

• Compounded medications are not FDA approved in any case. They are prepared for an individual patient on a prescription.
• The July committee vote was a recommendation. The FDA is not bound by it.
• The trade publication Pink Sheet reported on October 8 that staff in the FDA’s drug center said they would not recommend temporary compounding of these peptides.

Our BPC-157 FDA status page keeps a dated change log of each of these steps.

What safeguards are being discussed?

Three safeguards are on the table: disclosures to patients, reporting of serious side effects, and data collection on how the peptides are used. They come from the Alliance for Pharmacy Compounding, which says it has met with the FDA twice to ask for temporary permission for state-licensed pharmacies on those conditions. None of them is final, because the plan itself is not final.

What does this mean if you already have a prescription?

It means no change today. A news report about a draft plan is not a reason to start, stop, or adjust a medication.

• Keep following the directions on your prescription label.
• Questions about your own treatment belong with the provider who prescribed it. Rx Peps Direct patients can message their provider from the dashboard.
• If the rules change, the change will come from the FDA or the Department of Health and Human Services in writing, with a date.

What does this mean if you are thinking about starting?

It means the safe route is the same as it was last week: a prescription from a licensed provider, filled by a licensed pharmacy.

Products sold online as “research use only” are not made for people and are not a substitute for a prescribed medication. A temporary federal measure, if it arrives, would apply to pharmacies filling prescriptions. It would not make research products safe to use. See compounded peptides vs research peptides for the difference.

At Rx Peps Direct, a licensed provider reviews your health history before anything is prescribed. The visit is $39, there is no subscription, and we serve patients in 28 states plus Washington, DC.

What should you watch for next?

Watch for an official document, not a headline. Three things would mark a real change:

1. A written announcement from the White House, the FDA or HHS that names the peptides covered.
2. A stated start date and the conditions pharmacies must meet.
3. A notice in the Federal Register opening the permanent rule for public comment.

We will update this page when any of those is published.

Sources

As of October 9, 2026 there is no White House, HHS or FDA statement on this plan to link to. These are the sources behind this page.

1. The Washington Post. Trump administration paving way for temporary sale of some unapproved peptides. Rachel Roubein. October 7, 2026. washingtonpost.com
2. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
3. Alliance for Pharmacy Compounding. Peptide plan reportedly in the works. October 2026. a4pc.org
4. KFF Health News. Morning Briefing, Thursday, October 8, 2026. kffhealthnews.org
5. Pink Sheet. US FDA Staff Push Back Against Trump Administration Interim Peptide Dispensing Order. October 8, 2026. insights.citeline.com